JP2010526867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526867A5 JP2010526867A5 JP2010508005A JP2010508005A JP2010526867A5 JP 2010526867 A5 JP2010526867 A5 JP 2010526867A5 JP 2010508005 A JP2010508005 A JP 2010508005A JP 2010508005 A JP2010508005 A JP 2010508005A JP 2010526867 A5 JP2010526867 A5 JP 2010526867A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- hydrogen atom
- methyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 230000000069 prophylactic effect Effects 0.000 claims 7
- 150000008318 pyrimidones Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- -1 Z is a bond Chemical group 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 claims 1
- MXIKUYLCSDTPHM-UHFFFAOYSA-N 2-chloro-5-fluoro-n-[2-(1-methyl-6-oxo-4-pyrimidin-4-ylpyrimidin-2-yl)ethyl]benzamide Chemical compound N=1C(C=2N=CN=CC=2)=CC(=O)N(C)C=1CCNC(=O)C1=CC(F)=CC=C1Cl MXIKUYLCSDTPHM-UHFFFAOYSA-N 0.000 claims 1
- LFLQEPGIIKYDQT-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-n-[2-(1-methyl-6-oxo-4-pyrimidin-4-ylpyrimidin-2-yl)ethyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NCCC1=NC(C=2N=CN=CC=2)=CC(=O)N1C LFLQEPGIIKYDQT-UHFFFAOYSA-N 0.000 claims 1
- BFMQWOZRBANLBB-UHFFFAOYSA-N 4-chloro-2-methoxy-n-[2-(1-methyl-6-oxo-4-pyrimidin-4-ylpyrimidin-2-yl)ethyl]benzamide Chemical compound COC1=CC(Cl)=CC=C1C(=O)NCCC1=NC(C=2N=CN=CC=2)=CC(=O)N1C BFMQWOZRBANLBB-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- CFNPCAIKLGYFHK-UHFFFAOYSA-N COC1=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C(C=C1)OC.FC1=CC(=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C1)OC Chemical compound COC1=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C(C=C1)OC.FC1=CC(=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C1)OC CFNPCAIKLGYFHK-UHFFFAOYSA-N 0.000 claims 1
- CWURRCFSTYHBRS-UHFFFAOYSA-N FC1=CC=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C1.C(C1=CC=CC=C1)OC(NCCC=1N(C(C=C(N1)C1=NC=NC=C1)=O)C)=O Chemical compound FC1=CC=C(C(=O)NCCC=2N(C(C=C(N2)C2=NC=NC=C2)=O)C)C=C1.C(C1=CC=CC=C1)OC(NCCC=1N(C(C=C(N1)C1=NC=NC=C1)=O)C)=O CWURRCFSTYHBRS-UHFFFAOYSA-N 0.000 claims 1
- 102000001267 GSK3 Human genes 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- DLGMBUKDWMLQSM-UHFFFAOYSA-N n-[2-(1-methyl-6-oxo-4-pyrimidin-4-ylpyrimidin-2-yl)ethyl]naphthalene-2-carboxamide Chemical compound C=1C(=O)N(C)C(CCNC(=O)C=2C=C3C=CC=CC3=CC=2)=NC=1C1=CC=NC=N1 DLGMBUKDWMLQSM-UHFFFAOYSA-N 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 CC*C(N=C(*)N1*)=C(*)C1=O Chemical compound CC*C(N=C(*)N1*)=C(*)C1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290626.6 | 2007-05-16 | ||
| EP07290626A EP1992625A1 (en) | 2007-05-16 | 2007-05-16 | Arylamide pyrimidone compounds |
| PCT/IB2008/002458 WO2008155670A2 (en) | 2007-05-16 | 2008-05-14 | Arylamide pyrimidone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526867A JP2010526867A (ja) | 2010-08-05 |
| JP2010526867A5 true JP2010526867A5 (enExample) | 2011-06-16 |
| JP5508257B2 JP5508257B2 (ja) | 2014-05-28 |
Family
ID=38596326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508005A Active JP5508257B2 (ja) | 2007-05-16 | 2008-05-14 | アリールアミドピリミドン化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8598187B2 (enExample) |
| EP (2) | EP1992625A1 (enExample) |
| JP (1) | JP5508257B2 (enExample) |
| KR (1) | KR20100016511A (enExample) |
| CN (1) | CN101679379A (enExample) |
| AR (1) | AR066604A1 (enExample) |
| AU (1) | AU2008264902A1 (enExample) |
| BR (1) | BRPI0811597A2 (enExample) |
| CA (1) | CA2687156A1 (enExample) |
| EA (1) | EA200971063A1 (enExample) |
| IL (1) | IL201625A0 (enExample) |
| MX (1) | MX2009012377A (enExample) |
| NZ (1) | NZ581164A (enExample) |
| TW (1) | TW200948802A (enExample) |
| WO (1) | WO2008155670A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145423A (en) | 1976-02-10 | 1979-03-20 | Rhone-Poulenc Industries | Pyrimidinyl-1,2-dithiole compounds and anti-bilharzia compositions thereof |
| US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
| JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| CN1247586C (zh) | 2001-09-21 | 2006-03-29 | 赛诺菲安万特 | 治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物 |
| ZA200505258B (en) | 2002-12-16 | 2006-09-27 | Mitsubishi Pharma Corp | 3-Substituted-4-pyrimidone derivatives |
| EP1603910B1 (en) | 2003-03-07 | 2009-08-26 | Sanofi-Aventis | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
| EP1790649A1 (en) | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
-
2007
- 2007-05-16 EP EP07290626A patent/EP1992625A1/en not_active Withdrawn
-
2008
- 2008-05-14 JP JP2010508005A patent/JP5508257B2/ja active Active
- 2008-05-14 KR KR1020097023695A patent/KR20100016511A/ko not_active Withdrawn
- 2008-05-14 EP EP08807123.8A patent/EP2160388B1/en active Active
- 2008-05-14 CN CN200880016007A patent/CN101679379A/zh active Pending
- 2008-05-14 AU AU2008264902A patent/AU2008264902A1/en not_active Abandoned
- 2008-05-14 NZ NZ581164A patent/NZ581164A/en not_active IP Right Cessation
- 2008-05-14 BR BRPI0811597A patent/BRPI0811597A2/pt not_active IP Right Cessation
- 2008-05-14 WO PCT/IB2008/002458 patent/WO2008155670A2/en not_active Ceased
- 2008-05-14 MX MX2009012377A patent/MX2009012377A/es not_active Application Discontinuation
- 2008-05-14 CA CA002687156A patent/CA2687156A1/en not_active Abandoned
- 2008-05-14 EA EA200971063A patent/EA200971063A1/ru unknown
- 2008-05-16 AR ARP080102085A patent/AR066604A1/es unknown
- 2008-05-16 TW TW097118157A patent/TW200948802A/zh unknown
-
2009
- 2009-10-19 IL IL201625A patent/IL201625A0/en unknown
- 2009-10-27 US US12/606,662 patent/US8598187B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526867A5 (enExample) | ||
| US11401259B2 (en) | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | |
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| RU2012148818A (ru) | 2,5,6,7-тетрагидро-[1,4]оксазепин-3-илмаины или 2,3,6,7-тетрагидро-[1,4]оксазепин-5-иламины | |
| JP6532607B2 (ja) | スルホンアミド化合物又はその塩 | |
| RU2001130169A (ru) | Производные карбаминовой кислоты и их применение в качестве лигандов метаботропных глутаматных рецепторов | |
| WO2013066833A1 (en) | Compounds and methods to inhibit histone deacetylase (hdac) enzymes | |
| RU2011125376A (ru) | Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы | |
| WO2013066839A2 (en) | Compounds and methods | |
| CA2787018A1 (en) | Inhibitors of histone deacetylase (hdac) enzymes | |
| TW200524575A (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
| TW201240970A (en) | Pyrazole compounds and thiazole compounds as protein kinases inhibitors | |
| WO2016082713A1 (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| US10577362B2 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| JP2007519695A5 (enExample) | ||
| JP2021500340A5 (enExample) | ||
| JP2011510972A5 (enExample) | ||
| JP2009541404A5 (enExample) | ||
| RU2013125338A (ru) | Производные триазола в качестве лигандов рецепторов гамк | |
| JP2016525104A5 (enExample) | ||
| CN114650986A (zh) | 2-氨基喹唑啉酮衍生物 | |
| US20240083912A1 (en) | Compounds and their uses as mif inhibitors | |
| CN103497179B (zh) | 含苯并咪唑结构单元的嘧啶衍生物及其制备方法和用途 | |
| Kaur et al. | Synthesis of fusidic acid bioisosteres as antiplasmodial agents and molecular docking studies in the binding site of elongation factor-G |